CD274 and endometrial cancer: A clinical trial investigated the efficacy of PARP inhibitors talazoparib in combination with the PD-L1 inhibitor avelumab in 35 patients with recurrent MSS endometrial cancer, with a relatively low ORR (11.4%) and 6-month PFS rate (22.9%) [27].